Hikma Pharmaceuticals (HKMPF) announced overnight that its wholly owned U.S. subsidiary Hikma Pharmaceuticals USA has received approval from the Food and Drug Administration for its Icosapent Ethyl Capsules, the generic equivalent to Amarin’s (AMRN) Vascepa. In March 2020, the United States District Court for the District of Nevada invalidated six Vascepa patents owned by Amarin. The district court decision is currently being appealed. Brian Hoffmann, Hikma’s President of Generics said, “The approval for our generic version of Vascepa is an important milestone towards bringing this product to market. This approval demonstrates the strength of our regulatory capabilities and our commitment to provide patients and healthcare providers in the US with the high-quality medicines they need.” Shares of Amarin closed Thursday down 18c to $7.28.